Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia

Area of Science:

• Hepatology and Endocrinology
• Cancer Research
• Pharmacology

Background:

• Previous research suggests metformin and statins individually may lower hepatocellular carcinoma (HCC) risk in diabetic patients.
• Hepatocellular carcinoma (HCC) remains a significant concern for patients with type 2 diabetes mellitus (DM).

Purpose of the Study:

• To investigate the potential synergistic effect of combining metformin and statin therapy in reducing HCC incidence among type 2 DM patients.
• To evaluate the impact of specific statin types (simvastatin, atorvastatin, rosuvastatin) and their combinations with metformin on HCC risk and comorbidities.

Main Methods:

• A cohort study involving newly diagnosed type 2 DM patients without prior malignancy.
• Frequency matching of a non-cancer cohort (4:1 ratio) with the HCC cancer cohort based on age, sex, DM duration, and index date.
• Analysis of odds ratios (OR) and 95% confidence intervals (CI) to assess the risk reduction associated with statin monotherapy, metformin-statin combinations, and HCC comorbidities.

Main Results:

• Statin use was associated with a 63% decreased risk of HCC (OR = 0.37).
• Specific statins (simvastatin, atorvastatin, rosuvastatin) and their combinations with metformin demonstrated significant reductions in HCC risk.
• Combination therapy of metformin and simvastatin notably decreased HCC comorbidities (OR = 0.26).

Conclusions:

• Combination therapy of metformin and statins shows promise in reducing HCC incidence and comorbidities in type 2 DM patients.
• The effectiveness of metformin-statin combinations may vary, with metformin and simvastatin showing particular benefit for comorbidities.
• Further research is needed to confirm these findings, especially regarding regional variations in efficacy.